Header Forschung

Department of Dermatology, Dermatooncology

The Department of Dermatology with Prof. Stefan Beissert as Head of Department and Prof. Friedegund Meier as Head of Dermatooncology sees more than 3.000 patients with advanced skin cancer annually in the outpatient department of the University Cancer Center Dresden. Clinical trials including investigator initiated trials range from phase I to IV for patients with advanced skin cancer, in particular for patients with metastatic melanoma. In collaboration with the departments of radiooncology and neurosurgery and the institutes of pathology and immunology, the translational research focuses on understanding and overcoming therapy resistance in metastatic melanoma, new treatment strategies for melanoma brain metastases and radiation therapy combined with targeted therapy or immunotherapy. The EPIDASC project of the "Nationale Versorgungskonferenz Hautkrebs" works on evidence-based information and decision aids for patients with skin cancer. The efforts and expertise of physicians and scientists are combined to offer patients with skin cancer the best possible cancer care.

Derma2

Induction of endoplasmic reticulum (ER) stress as a strategy for melanoma therapy; vemurafenib induces ER stress in SKMEL19 melanoma cells. Copyright: Prof. Friedegund Meier

Derma1

A phase II study of stereotactic radiosurgery and vemurafenib plus cobimetinib in patients with active BRAFV600-mutant melanoma brain metastases. Copyright: Prof. Friedegund Meier

Gellrich FF, Schmitz M, Beissert S, Meier F. Anti-PD-1 and Novel Combinations in the Treatment of Melanoma-An Update. J. Clin. Med. 2020, 9(1), 223. doi: 10.3390/jcm9010223

Vetma V, Guttà C, Peters N, Praetorius C, Hutt M, Seifert O, Meier F, Kontermann R, Kulms D, Rehm M. Convergence of pathway analysis and pattern recognition predicts sensitization to latest generation TRAIL therapeutics by IAP  antagonism. Cell Death & Differentiation volume 27, pages2417–2432(2020). doi: 10.1038/s41418-020-0512-5

Zimmer L, Livingstone E, Hassel JC, Fluck M, Eigentler T, Loquai C, Haferkamp S, Gutzmer R, Meier F, Mohr P, Hauschild A, Schilling B, Menzer C, Kieker F, Dippel E, Rösch A, Simon JC, Conrad B, Körner S, Windemuth-Kieselbach C, Schwarz L, Garbe C, Becker JC, Schadendorf D. Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2020 May 16;395(10236):1558-1568. doi: 10.1016/S0140-6736(20)30417-7

Migden MR, Khushalani NI, Chang ALS, Lewis KD, Schmults CD, Hernandez-Aya L, Meier F, Schadendorf D, Guminski A, Hauschild A, Wong DJ, Daniels GA, Berking C, Jankovic V, Stankevich E, Booth J, Li S, Weinreich DM, Yancopoulos GD, Lowy I, Fury MG, Rischin D. Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial. Lancet Oncol. 2020 Feb;21(2):294-305. doi: 10.1016/S1470-2045(19)30728-4

Livingstone E, Zaremba A, Horn S, Ugurel S, Casalini B, Schlaak M, Hassel JC, Herbst R, Utikal JS, Weide B, Gutzmer R, Meier F, Koelsche C, Hadaschik E, Sucker A, Reis H, Merkelbach-Bruse S, Siewert M, Sahm F, von Deimling A, Cosgarea I, Zimmer L, Schadendorf D, Schilling B, Griewank KG. GNAQ and GNA11 mutant nonuveal melanoma: a subtype distinct from both cutaneous and uveal melanoma. Br J Dermatol. 2020 Nov;183(5):928-939. doi: 10.1111/bjd.18947

Gutzmer R, Vordermark D, Hassel JC, Krex D, Wendl C, Schadendorf D, Sickmann T, Rieken S, Pukrop T, Höller C, Eigentler TK, Meier F. Melanoma brain metastases - Interdisciplinary management recommendations 2020. Cancer Treat Rev. 2020 Sep;89:102083. doi: 10.1016/j.ctrv.2020.102083

Amaral T, Kiecker F, Schaefer S, Stege H, Kaehler K, Terheyden P, Gesierich A, Gutzmer R, Haferkamp S, Uttikal J, Berking C, Rafei-Shamsabadi D, Reinhardt L, Meier F, Karoglan A, Posch C, Gambichler T, Pfoehler C, Thoms K, Tietze J, Debus D, Herbst R, Emmert S, Loquai C, Hassel JC, Meiss F, Tueting T, Heinrich V, Eigentler T, Garbe C, Zimmer L. Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG study in 380 patients. J Immunother Cancer. 2020 Mar;8(1):e000333. doi: 10.1136/jitc-2019-000333